Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death

Haley HieronymusCharles L Sawyers


The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is associated with recurrence of primary prostate cancer. Whether CNA burden is associated with prostate cancer survival or outcomes in other cancers is unknown. We analyzed the CNA landscape of conservatively treated prostate cancer in a biopsy and transurethral resection cohort, reflecting an increasingly common treatment approach. We find that CNA burden is prognostic for cancer-specific death, independent of standard clinical prognosticators. More broadly, we find CNA burden is significantly associated with disease-free and overall survival in primary breast, endometrial, renal clear cell, thyroid, and colorectal cancer in TCGA cohorts. To assess clinical applicability, we validated these findings in an independent pan-cancer cohort of patients whose tumors were sequenced using a clinically-certified next generation sequencing assay (MSK-IMPACT), where prognostic value varied based on cancer type. This prognostic association was affected by incorporating tumor purity in some cohorts. Overall, CNA burden of primary and metastatic tumors is a prognostic factor, potentially modulated by sample purity and measurable by current clinical sequencing.


Nov 2, 2006·British Journal of Cancer·J CuzickUNKNOWN Transatlantic Prostate Group
Feb 19, 2010·Nature·Rameen BeroukhimMatthew Meyerson
Jun 29, 2010·Cancer Cell·Barry S TaylorWilliam L Gerald
May 1, 2012·Nature Biotechnology·Scott L CarterGad Getz
Jul 20, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Jun 25, 2013·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 28, 2013·Nature Genetics·Travis I ZackRameen Beroukhim
Jul 16, 2014·Proceedings of the National Academy of Sciences of the United States of America·Haley HieronymusCharles L Sawyers
Aug 28, 2014·Genome Biology·Davide PrandiFrancesca Demichelis
Nov 25, 2014·Cell·UNKNOWN Cancer Genome Atlas Research Network
Sep 9, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E CastroUNKNOWN UKGPCS, EMBRACE and IMPACT studies
Oct 10, 2015·Cell·Giovanni CirielloCharles M Perou
Oct 31, 2015·BioData Mining·Hugo Gómez-RuedaVictor Trevino
Nov 7, 2015·Cell·UNKNOWN Cancer Genome Atlas Research Network
Nov 26, 2015·Nature Reviews. Clinical Oncology·Håvard E DanielsenMarco Novelli
Jan 19, 2016·Molecular Oncology·Ellen HeitzerMichael R Speicher
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald C ChenSuneil Jain
Mar 10, 2016·Nature Reviews. Urology·Jeffrey J TosoianStacy Loeb
May 12, 2016·Cancer Cell·Darjus F TschaharganehScott W Lowe
Sep 13, 2016·European Urology·Jonathan S BrajtbordMatthew R Cooperberg
Feb 12, 2017·Cell·David M HymanJosé Baselga
Apr 27, 2017·The New England Journal of Medicine·Mariam Jamal-HanjaniUNKNOWN TRACERx Consortium
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Feb 22, 2018·Current Treatment Options in Oncology·Paulo G BergerotSumanta Kumar Pal
May 5, 2018·Genes & Cancer·Alexander PearlmanHarry Ostrer
Aug 15, 2018·Nature Genetics·Geoff MacintyreJames D Brenton

❮ Previous
Next ❯


Sep 25, 2019·Nature Reviews. Genetics·Uri Ben-David, Angelika Amon
Mar 27, 2020·Medical Sciences : Open Access Journal·Ugo TestaElvira Pelosi
Mar 12, 2020·International Journal of Cancer. Journal International Du Cancer·Bo WuDongwen Wang
Dec 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott E EggenerHimisha Beltran
Feb 11, 2020·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Gregory D JonesGaetano Rocco
Jun 12, 2019·Nature·Sarah C Johnson, Sarah E McClelland
May 6, 2020·Cancers·Maud de DieuleveultBenoit Miotto
Jul 9, 2020·NPJ Precision Oncology·Colin M CourtVatche G Agopian
Sep 4, 2020·Nature·Thomas B K WatkinsCharles Swanton
Aug 17, 2020·Communications Biology·Benjamin S SimpsonHayley C Whitaker
May 16, 2019·Proceedings of the National Academy of Sciences of the United States of America·Konrad H StopsackAngelika Amon
Dec 12, 2019·Frontiers in Oncology·Matthew J Ryan, Rohit Bose
Feb 2, 2020·BMC Cancer·Zhenggang WuHong Xue
May 2, 2020·Scientific Reports·Zachary S BuchwaldHui-Kuo G Shu
Oct 24, 2018·Cold Spring Harbor Perspectives in Medicine·Michael M Shen, Mark A Rubin
Dec 5, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Goutam ChakrabortyPhilip W Kantoff
Mar 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Konrad H StopsackWassim Abida
Oct 11, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shuxiong ZengChuanliang Xu
Nov 16, 2020·Current Oncology Reports·Beatriz Rosales-RodríguezHaydeé Rosas-Vargas
Jan 29, 2021·Nature·Yael Cohen-SharirUri Ben-David
Feb 12, 2021·Nature Communications·Yiqun ZhangChad J Creighton
Jan 13, 2021·Nature Reviews. Cancer·Anand VasudevanJason M Sheltzer
Nov 15, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander SemaanPaola A Guerrero

❮ Previous
Next ❯

Datasets Mentioned


Methods Mentioned

exome sequencing

Software Mentioned


Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.